Horan Securities’s Teva Pharmaceuticals TEVA Stock Holding History

Horan Securities’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-510	Closed	-$3.84K	–	605
2023 Q2	$3.84K	Hold	510	–	–	﹤0.01%	509
2023 Q1	$4.51K	Hold	510	–	–	﹤0.01%	479
2022 Q4	$4.65K	Hold	510	–	–	﹤0.01%	461
2022 Q3	$4K	Hold	510	–	–	﹤0.01%	432
2022 Q2	$4K	Hold	510	–	–	﹤0.01%	457
2022 Q1	$5K	Hold	510	–	–	﹤0.01%	385
2021 Q4	$4K	Buy	+510	New	+$4.6K	﹤0.01%	411
2021 Q2	$5K	Hold	510	–	–	﹤0.01%	361
2021 Q1	$6K	Hold	510	–	–	0.01%	316
2020 Q4	$5K	Hold	510	–	–	﹤0.01%	310
2020 Q3	$5K	Hold	510	–	–	0.01%	266
2020 Q2	$6K	Buy	510 +500	+5,000%	+$5.66K	0.01%	231
2020 Q1	$0	Buy	+10	New	+$102	﹤0.01%	286
2019 Q4	–	Sell	-10	Closed	–	–	209
2019 Q3	$0	Hold	10	–	–	﹤0.01%	291
2019 Q2	$0	Hold	10	–	–	﹤0.01%	299
2019 Q1	$0	Hold	10	–	–	﹤0.01%	239
2018 Q4	$0	Hold	10	–	–	﹤0.01%	234
2018 Q3	$0	Buy	+10	New	+$232	﹤0.01%	224
2018 Q1	–	Sell	-4,000	Closed	-$88K	–	213
2017 Q4	$88K	Buy	+4,000	New	+$60.2K	0.08%	43

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

IAM

Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

SPC

Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Horan Securities's TEVA Position: Q3 2023 in Review

Horan Securities sold out of Teva Pharmaceuticals (TEVA) in Q3 2023, closing a stake of 510 shares — an estimated $3.84K sold.

Horan Securities first reported a position in TEVA in Q4 2017 and held it in 19 quarters. The position peaked at $88K in Q4 2017. 435 funds tracked by Wall St. Rank hold TEVA as of Q3 2023.

Horan Securities reported no remaining Teva Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Horan Securities sold 510 Teva Pharmaceuticals shares in Q3 2023, an estimated $3.84K.
Horan Securities first reported a position in Teva Pharmaceuticals in Q4 2017 and held it in 19 quarters.
Horan Securities's Teva Pharmaceuticals position peaked at $88K in Q4 2017.
435 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2023.

Based on Horan Securities's 13F filing for Q3 2023, filed 1 Nov 2023.